1. Baseline characteristics of study patients.
| Characteristics | Full cohort (n=116) | NLR<2.94 (n=85) | NLR≥2.94 (n=31) | P* |
| IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; TTP, time-to-progression; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase; mMDSC, monocytic myeloid-derived suppressor cells; gMDSC, granulocytic myeloid-derived suppressor cells; *, P-values represent comparison between NLR<2.94 and NLR≥2.94 groups. **, Baseline LDH levels were available in 107 patients: 77 and 30 patients in NLR<2.94 and NLR≥2.94 groups, respectively. | ||||
| Age (year) [median (IQR)] | 58 (47−63) | 57 (47−63) | 58 (49−63) | 0.689 |
| Male gender [n (%)] | 71 (61.2) | 51 (60.0) | 20 (64.5) | 0.821 |
| ECOG PS [n (%)] | 0.764 | |||
| 0−1 | 108 (93.1) | 80 (94.1) | 28 (90.3) | |
| 2 | 8 (6.9) | 5 (5.9) | 3 (9.7) | |
| First-line TTP (month) [median (IQR)] | 6.5 (3.9−12.1) | 7.9 (4.7−13.2) | 4.2 (1.6−6.2) | <0.001 |
| NLR [median (IQR)] | 2.0 (1.4−3.0) | 1.7 (1.2−2.1) | 4.4 (3.6−5.4) | <0.001 |
Hemoglobin (g/dL) (
)
|
11.3±1.7 | 11.6±1.7 | 10.6±1.6 | 0.008 |
| LDH elevation [n (%)]** | 36 (33.6) | 24 (31.2) | 12 (40.0) | 0.522 |
| mMDSC (count/µL) [median (IQR)] | 154.8 (29.8−306.7) | 123.9 (22.2−238.7) | 255.2 (100.1−81.2) | 0.001 |
| gMDSC (count/µL) [median (IQR)] | 1,953.1 (937.0−2,948.0) | 1,480.0 (98.5−2,561.6) | 2,508.0 (1,770.9−5,523.4) | 0.001 |